

DM-39L: JAK Inhibitors in Alopecia Areata: How to Use in Varied Clinical Scenarios

Toolkit

Alopecia Areata: Etiology and Epidemiology

Reference	URL
Aita VM, Christiano AM. The genetics of alopecia areata. <i>Dermatol Ther.</i> 2001;14:329-339.	https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1529-8019.2001.01041.x
Alopecia Areata. National Alopecia Areata Foundation.	https://www.naaf.org/alopecia-areata
Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. <i>Clin Cosmet Investig Dermatol.</i> 2020;13:259-266.	https://www.dovepress.com/a-large-cross-sectional-survey-study-of-the-prevalence-of-alopecia-are-peer-reviewed-fulltext-article-CCID
Divito SJ, Kupper TS. Inhibiting Janus kinases to treat alopecia areata. <i>Nat Med.</i> 2014;20:989-990.	https://www.nature.com/articles/nm.3685
Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. <i>J Clin Invest.</i> 2007;117:2019-2027.	https://www.jci.org/articles/view/31942
Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? <i>J Am Acad Dermatol.</i> 1998;38:418-425.	https://www.jaad.org/article/S0190-9622(98)70499-2/fulltext
Lepe K, Zito PM. Alopecia areata. <i>StatPearls.</i> Last update August 14, 2023.	https://www.ncbi.nlm.nih.gov/books/NBK537000/
Paus R, Cotsarelis G. The biology of hair follicles. <i>N Engl J Med.</i> 1999;341:491-497.	https://www.nejm.org/doi/10.1056/NEJM199908123410706
Perrett C, Bröcker EB, Wiesner-Menzel L, Happle R. In situ demonstration of T cells in alopecia areata. <i>Arch Dermatol Res.</i> 1982;273:155-158.	https://link.springer.com/article/10.1007/BF00509041
Petukhova L, Duvic M, Hordinsky M, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. <i>Nature.</i> 2010;466:113-117.	https://www.nature.com/articles/nature09114
Sibbald C. Alopecia areata: An updated review for 2023. <i>J Cutan Med Surg.</i> 2023;27:241–259.	https://journals.sagepub.com/doi/10.1177/12034754231168839
Sy N, Mastacouris N, Strunk A, Garg A. Overall and racial and ethnic subgroup prevalences of alopecia areata, alopecia totalis, and alopecia universalis. <i>JAMA Dermatol.</i> 2023;159:419-423.	https://jamanetwork.com/journals/jamadermatology/article-abstract/2801704
Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. <i>Nat Med.</i> 2014;20:1043-1049.	https://www.nature.com/articles/nm.3645

Conventional Treatment Strategies

Reference	URL
Chow CW, Rincón M, Davis RJ. Requirement for transcription factor NFAT in interleukin-2 expression. <i>Mol Cell Biol.</i> 1999;19:2300-2307.	https://www.tandfonline.com/doi/abs/10.1128/MC.B.19.3.2300
Cranwell WC, Lai VW, Photiou L, et al. Treatment of alopecia areata: An Australian expert consensus statement. <i>Australas J Dermatol.</i> 2019;60:163-170.	https://onlinelibrary.wiley.com/doi/10.1111/ajd.12941
Gengraf® (cyclosporin). Prescribing information. AbbVie Inc; 2021.	https://www.rxabbvie.com/pdf/gengraf-cap.pdf
Imuran® (azathioprine). Prescribing information. Sebelo Pharmaceuticals Inc; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016324s039lbl.pdf
Kenalog® (triamcinolone acetonide injectable suspension, USP). Prescribing information. Bristol-Myers Squibb Company; 2019.	https://www.bms.com/assets/packageinserts/pi/pi_kenalog-40-80.pdf
Lai VWY, Sinclair R. Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: A retrospective study of continuation rates in 138 patients. <i>J Eur Acad Dermatol Venereol.</i> 2020;34:2606-2612.	https://onlinelibrary.wiley.com/doi/10.1111/jdv.16858
Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. <i>J Am Acad Dermatol.</i> 2020;83:123-130.	https://www.jaad.org/article/S0190-9622(20)30375-3/fulltext
Messenger AG. Alopecia areata: Management. <i>UpToDate.</i> Last updated May 8, 2023.	https://www.uptodate.com/contents/alopecia-areata-management
Methotrexate. Prescribing Information. DAVA Pharmaceuticals, Inc; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf
Minoxidil (Topical) (Monograph).	https://www.drugs.com/monograph/minoxidil-topical.html
Olsen EA, Canfield D. SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. <i>J Am Acad Dermatol.</i> 2016;75:1268-1270.	https://www.jaad.org/article/S0190-9622(16)30729-0/fulltext
Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. <i>J Am Acad Dermatol.</i> 2018;78:15-24.	https://www.jaad.org/article/S0190-9622(17)31874-1/fulltext
Vañó-Galván S, Hermosa-Gelbard Á, Sánchez-Neila N, et al. Pulse corticosteroid therapy with oral dexamethasone for the treatment of adult alopecia totalis and universalis. <i>J Am Acad Dermatol.</i> 2016;74:1005-1007.	https://www.jaad.org/article/S0190-9622(15)02602-X/fulltext

Recent and Emerging Treatments – JAK inhibitors

Reference	URL
Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. <i>J Leukoc Biol.</i> 2018;104:499-514.	https://academic.oup.com/jleukbio/article-abstract/104/3/499/6935484
King B, Craiglow BG. Janus kinase inhibitors for alopecia areata. <i>J Am Acad Dermatol.</i> 2023;89(2 suppl):S29-S32.	https://www.jaad.org/article/S0190-9622(23)00988-X/fulltext
King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. <i>J Am Acad Dermatol.</i> 2021;85:379-387.	https://www.jaad.org/article/S0190-9622(21)00601-0/fulltext
King B, Guttman-Yassky E, Peeva E, et al. Safety and efficacy of ritlecitinib and brepocitinib in alopecia areata: Results from the crossover open-label extension of the ALLEGRO phase 2a trial. <i>JID Innov.</i> 2022;2:10015.	https://www.jidinnovations.org/article/S2667-0267(22)00064-9/pdf
King B, Mesinkovska NA, Senn MM, Mostaghimi A, Hamilton C, Cassella J. 42736 Safety assessments in the multinational phase 3 THRIVE-AA1 trial with CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata. <i>J Am Acad Dermatol.</i> 2023;89(3 suppl):AB85.	https://www.jaad.org/article/S0190-9622(23)01699-7/fulltext
King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. <i>N Engl J Med.</i> 2022;386:1687-1699.	https://www.nejm.org/doi/full/10.1056/nejmoa2110343
King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: A randomised, double-blind, multicentre, phase 2b-3 trial. <i>Lancet</i> 2023;401:1518-1529.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00222-2/fulltext
Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. <i>J Am Acad Dermatol.</i> 2004;51:440-447.	https://www.jaad.org/article/S0190-9622(03)04368-8/fulltext
Olsen EA, Kornacki D, Sun K, Hordinsky MK. Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study. <i>J Am Acad Dermatol.</i> 2020;82:412-419.	https://www.jaad.org/article/S0190-9622(19)32898-1/fulltext
Peeva E, Guttman-Yassky E, Banerjee A, et al. Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial. <i>J Am Acad Dermatol.</i> 2022;87:390-393.	https://www.jaad.org/article/S0190-9622(21)02964-9/fulltext
Senna MM, King B, Mesinkovska NA, Mostaghimi A, Hamilton C, Cassella J. 41701 Efficacy of the oral JAK1/JAK2 inhibitor CTP-543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata: Results from the multinational double-blind, placebo-controlled THRIVE-AA1 phase 3 trial. <i>J Am Acad Dermatol.</i> 2023;89(3 suppl):AB43.	https://www.jaad.org/article/S0190-9622(23)01534-7/fulltext

Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. <i>J Am Acad Dermatol</i> . 2018;78:15-24.	https://www.jaad.org/article/S0190-9622(17)31874-1/fulltext
Wyrwich KW, Kitchen H, Knight S, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. <i>Am J Clin Dermatol</i> . 2020;21:725-732.	https://link.springer.com/article/10.1007/s40257-020-00545-9

Psychosocial Considerations and Shared Decision-Making Approaches in AA

Reference	URL
Cipriani R, Perini GI, Rampinelli S. et al. Paroxetine in alopecia areata. <i>Int J Dermatol</i> . 2001;40:600-601.	https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-4362.2001.01261-3.x
Han JJ, Manjaly P, Lee KJ, et al. Physician values in alopecia areata treatment decision-making: A qualitative assessment. <i>JAAD Int</i> . 2022;11:14-23.	https://www.jaadinternational.org/article/S2666-3287(22)00162-6/fulltext
King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. <i>J Am Acad Dermatol</i> . 2022;86:359-364.	https://www.jaad.org/article/S0190-9622(21)02387-2/fulltext
Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. <i>J Am Acad Dermatol</i> . 2018;78:597-599.e2.	https://www.jaad.org/article/S0190-9622(17)32607-5/fulltext
Liu LY King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. <i>J Am Acad Dermatol</i> . 2018;79:556-558.e1.	https://www.jaad.org/article/S0190-9622(18)30183-X/fulltext
Reyes-Hadsall S, Drake L, Han JJ, et al. Shared decision-making, therapeutic choice, and decisional regret in patients with alopecia areata. <i>JAMA Dermatol</i> . 2022;158:1187-1191.	https://jamanetwork.com/journals/jamadermatology/article-abstract/2795016
Shapiro J. Current treatment of alopecia areata. <i>J Invest Derm Symp Proceed</i> . 2013;16:S42-S44.	https://www.jidsponline.org/article/S1087-0024(15)30530-X/fulltext
The SHARE approach: A model for shared decision-making fact sheet. Agency for Healthcare Research and Quality. Last reviewed September 2020.	https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html

All URLs accessed October 17, 2023